UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101

Akari Therapeutics

13/08/2026 22:33

Overview
UK-US oncology biotech's Q2 net loss widened yr/yr as R&D spending increased
Company raised $8.6 mln in financing during Q2, strengthening balance sheet
Company advanced AKTX-101 toward Phase 1 trial and expanded research collaboration

Outlook
Company plans to initiate Phase 1 clinical trial for AKTX-101 in mid-2027
Akari continues IND-enabling work to support AKTX-101 clinical development
Collaboration with Whitehawk Therapeutics aims to expand PH1 platform into dual-payload ADCs

Result Drivers
R&D SPENDING - Co said higher research and development expenses reflected expanded development and manufacturing activities for AKTX-101
PIPELINE ADVANCEMENT - Co continued IND-enabling work for AKTX-101, aiming for Phase 1 trial initiation in mid-2027
FINANCING INFLOW - Co raised about $8.6 mln in financing during the quarter, strengthening its balance sheet

Company press release: ID:nGNX2RDxxB

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Net Loss
 
$4.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Akari Therapeutics PLC is $30.00, about 317.8% above its August 12 closing price of $7.18

Reuters Recommended Reads
Aug 11 - UK's Mereo BioPharma Q2 loss narrows on lower R&D spending
Aug 13 - ADC Therapeutics Q2 loss narrows; cuts 17% workforce
Aug 13 - Aktis Oncology Q2 net loss widens on higher R&D, administrative costs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)